You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(00460.HK)夥藍晶微生物設合營 拓PHA醫美產品
阿思達克 01-21 09:48
四環醫藥(00460.HK)公佈,集團旗下?顏空間與藍晶微生物簽署協定成立合資公司,共同開發包括PHA微球及基於生物製造的再生醫學材料,雙方將共同完成產品的研發、合規化申報及後續商業化推廣。 PHA是一種存在於微生物胞內的天然聚酯,由羥基脂肪酸單體中的羧基和同種或不同種羥基脂肪酸單體中的羥基形成酯鍵連接起來的線性高分子。由PHA製成的手術縫合線、可吸收手術膜等醫療器械已在美國獲FDA批準上市。 公司認爲,成立合資公司使集團有機會提前入局合成生物學產業,邁出從醫美產業端向上遊原料端縱向延伸的一步,不僅將協助集團進一步完善其在醫美領域的產品矩陣,同時將大幅提高在非手術類醫美領域的綜合實力,增強核心競爭力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account